Rein Therapeutics Inc.
RNTX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $30,316 | $33,863 | $4 | $50 |
| - Cash | $4,048 | $5,722 | $7,428 | $12,865 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $26,268 | $28,141 | -$7,424 | -$12,815 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$5,581 | -$6,870 | -$5,609 | -$42,525 |
| % Margin | – | – | – | – |
| Net Income | -$5,581 | -$6,822 | -$5,501 | -$40,981 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.21 | -0.28 | -2,510.05 | -1.89 |
| % Growth | 25% | 100% | -132,706.9% | – |
| Operating Cash Flow | -$3,548 | -$6,418 | -$6,175 | -$4,812 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$3,548 | -$6,418 | -$6,175 | -$4,812 |